Hani Gabra PhD FRCPE FRCP (Born 15 January 1963) is a British oncologist and Professor Emeritus in Medical Oncology at Imperial College London. Prof Gabra currently practises as a Consultant Medical Oncologist at Portsmouth Hospitals NHS Trust, acting as Lead Clinician for Cancer Services.
Hani Gabra is a British academic medial oncologist and drug developer. He is Founder, board member and Chief Scientific Officer of Papyrus Therapeutics Inc., an emerging biotech company focussed on extra-cellular tumour suppressor therapies for cancer. He is also Professor Emeritus in Medical Oncology at Imperial College London (2020-) and adjunct professor at the Centre for Cancer Biomarkers at the University of Bergen in Norway.
From 2019 to 2021 he was Chief Medical Officer for BerGenBio ASA having previously held the position of Chief Physician Scientist and Vice President / Head of the Clinical Discovery Unit in Early Clinical Development within the IMED Biotech Unit at AstraZeneca in Cambridge, UK (2017–19).
Previously he was Professor of Medical Oncology at Imperial College London and Honorary Consultant Medical Oncologist at Imperial College Healthcare NHS Trust, based at the Hammersmith Campus of Imperial College (2003–20).Until May 2017 he was Head of the Molecular Therapeutics Unit, Deputy Head of the Division of Cancer and Director of the Ovarian Cancer Action Research Centre at Imperial College, and at Imperial College Healthcare NHS Trust he was also Head of Medical Oncology and Chair of the Cancer Research Committee. Until May 2017 he was also associate director and Lead of the Cancer Division (Division 1) of the National Institute for Health and Care Research (NIHR) Clinical Research Network for North West London.
Hani was educated at Carluke High School and studied medicine at the University of Glasgow, graduating with a BSc (Hons) in Molecular Biology and MB ChB in 1987. After obtaining MRCP(UK) in 1990, he undertook an MSc in Clinical Oncology and a PhD in Molecular Oncology from the University of Edinburgh. He then completed his specialist training in Cancer Medicine in Edinburgh and was CRUK Clinical Scientist and Consultant Medical Oncologist at the CRUK Edinburgh Medical Oncology Unit from 1998 to 2003, following which he took up his Chair appointment at Imperial College.
He is a Fellow of the Royal College of Physicians of Edinburgh and London.
His research is involved in trying to understand the role of tumour suppressor genes in ovarian cancer, particularly how OPCML regulates networks of receptor tyrosine kinases and how WWOX acts to regulate taxane sensitivity.
His clinical / translational interests relate to the understanding of platinum resistance in ovarian cancer, and he has developed several molecular targets whose inhibition can reverse platinum resistance from laboratory to clinic; such targets include AKT, MTOR, HDAC4, STAT1 and the Folate Receptors.
Until September 2017 he was founding President of the European Translational Ovarian Cancer Network (EUTROC), a multinational group that undertakes science in ovarian cancer clinical trials, principally in the context of complex phase II clinical trials.
He previously sat on CRUK CTAAC funding committee for the UK and the INCa Scientific Evaluation Committee, Institut National Du Cancer of France
He has been on the Editorial Boards of several journals including Gynecologic Oncology and the European Journal of Cancer .
Sellar, Grant C; Watt, Karen P; Rabiasz, Genevieve J; Stronach1, Euan A; Li, Li; Miller, Eric P; Massie, Charles E; Gabra, Hani; et al. (2003). "OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer". Nature Genetics. 34 (3): 337–343. doi:10.1038/ng1183. PMID 12819783. S2CID 24411276.{{cite journal}}: CS1 maint: numeric names: authors list (link)
John Gordon McVie was an international authority on the treatment and research of cancer. He wrote over 350 peer-reviewed articles, editorials and books. McVie was born in Glasgow, Scotland and died of non-Hodgkin lymphona and COVID-19 in Bristol, England.
Professor David James Kerr CBE is a British Cancer Researcher. His primary area of research is treatment and management of colorectal cancer.
Sir Gordon William Duff, is a British medical scientist and academic. He was principal of St Hilda's College, Oxford, from 2014 to 2021. He was Lord Florey Professor of Molecular Medicine at the University of Sheffield from 1991 to 2014.
Christopher M. Nutting is a British Professor of Clinical Oncology and medical consultant, specializing in head and neck cancers, who has helped develop Intensity-Modulated Radiotherapy (IMRT), an advanced form of Radiation therapy.
The Edinburgh Cancer Research Centre (ECRC), also known as the University of Edinburgh Cancer Research Centre, is a center for basic, translational and clinical cancer research located in Edinburgh, Scotland. ECRC constitutes a part of the Institute of Genetics & Molecular Medicine (IGMM) and is positioned in direct proximity of the Western General Hospital, where most of its clinical activities take place.
Dr. Kodaganur S. Gopinath, MS, FAMS, FRCS (Edin) is an Indian surgical oncologist, known for his pioneering work on oncological research. He is a recipient of many awards including Dr. B. C. Roy Award, considered to be the premier medical honour in the country. The President of India recognised his services to the field of oncology, by awarding him the fourth highest civilian award, Padma Shri, in 2010.
Ian Jacobs is an academic, medical doctor, gynaecological oncologist, charity founder and university leader from the UK, with dual British and Australian citizenship.
Sven Becker is a German gynaecologist, gynaecologic surgeon, and oncologist.
Branimir Ivan "Brandy" Sikic is an American medical doctor and scientist at Stanford University School of Medicine. He is an oncologist and cancer pharmacologist, and has served as a faculty member at Stanford University since 1979. His research spans basic, translational, and clinical research and investigates the mechanisms of drug resistance and the development of new anticancer therapies.
Caroline Dive is a British cancer research scientist. Dive is Professor of Cancer Pharmacology at the University of Manchester, Deputy Director of the Cancer Research UK (CRUK) Manchester Institute, Director of the CRUK Manchester Institute Cancer Biomarker Centre and co-director of the CRUK Lung Cancer Centre of Excellence. She is the current President of The European Association for Cancer Research (EACR).
(Robert) Charles Swanton is British physician scientist specialising in oncology and cancer research. Swanton is a senior group leader at London's Francis Crick Institute, Royal Society Napier Professor in Cancer and thoracic medical oncologist at University College London and University College London Hospitals, co-director of the Cancer Research UK (CRUK) Lung Cancer Centre of Excellence, and Chief Clinician of Cancer Research UK.
Elizabeth Ruth Plummer is a Professor of Experimental Cancer Medicine at Newcastle University and an oncologist specialising in treating patients with melanoma. Based in Newcastle, she directs the Sir Bobby Robson Cancer Trials Research Centre, set up by the Sir Bobby Robson Foundation to run early-stage clinical trials.v Plummer and the Newcastle team won a 2010 Translational Cancer Research Prize from Cancer Research UK for work using rucaparib to treat ovarian cancer. Plummer was elected as a fellow of the UK's Academy of Medical Sciences in 2018.
Usha Menon is Professor of Gynaecological Cancer at University College London, described as "one of Britain’s foremost specialists in gynaecological cancer".
Daniel Hochhauser is a British oncologist, and Kathleen Ferrier Professor of Medical Oncology at University College London.
Professor Carlos Caldas is a clinician scientist and Professor of Cancer Medicine at the University of Cambridge. He is the Chair of Cancer Medicine at the University of Cambridge, an Honorary Consultant Medical Oncologist at Addenbrooke's Hospital and Director of the Cambridge Breast Cancer Research Unit. He is a fellow of Robinson College, Cambridge and an Emeritus Senior Investigator at the National Institute for Health Research (NIHR).
The University of Glasgow's Glasgow Precision Oncology Laboratory (GPOL) is a molecular research facility that partners with the NHS and industry to perform research into the development of novel therapeutic strategies, the creation of pan-cancer genomic assays and provide knowledge transfer for healthcare systems to enable them to develop landscapes for therapeutic testing in cancer.
Professor James D Brenton is a clinician scientist and Senior Group Leader at the Cancer Research UK Cambridge Institute and Professor of Ovarian Cancer Medicine in the Department of Oncology, University of Cambridge. He is an Honorary Consultant in Medical Oncology at Addenbrooke's Hospital, Cambridge University Hospitals, Ovarian Cancer Domain Lead for the 100,000 Genomes Project by Genomics England, and co-founder and Clinical Advisor to Inivata Ltd, a clinical cancer genomics company.
Sarah Coupland is an Australian-born pathologist and professor who is the George Holt Chair in Pathology at the University of Liverpool. Coupland is an active clinical scientist whose research focuses on the molecular genetics of cancers, with particular interests in uveal melanoma, conjunctival melanoma, intraocular and ocular adnexal lymphomas and CNS lymphoma. Coupland is also an NHS Honorary Consultant Histopathologist at the Royal Liverpool University Hospital. Since 2006, Coupland has been head of the Liverpool Ocular Oncology Research Group; from which she runs a multidisciplinary oncology research group focussing on Uveal melanoma, based in the Department of Molecular and Clinical Cancer Medicine at the University of Liverpool. Her research laboratory is currently located in the Institute of Translational Medicine From April 2014 to December 2019, Coupland was also Director of the North West Cancer Research Centre, @UoL. In both 2019 and 2020, Coupland was included on the 'Pathology Powerlist' on The Pathologist website.
Sarah Blagden is a Professor of Experimental Oncology at the University of Oxford. Her laboratory research is in investigating post-transcriptional mechanisms for ovarian cancer behavior. Her clinical research is in conducting early phase trials in novel cancer therapeutics for people with advanced malignancies.
M D Ray is an Indian Author and Surgical oncologist who designed 4 Onco surgical techniques adopted internationally.
| Authority control databases: Academics |
|---|
